OneSource Specialty Pharma Ltd
OneSource Specialty Pharma Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28.
From OneSource Specialty Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin.
- Strong order book supports significant capacity expansion from 40 million to over 90 million units by December 2025.
- FY 2026 is a transition year with lumpy revenue due to regulatory approvals; stronger H2 expected, mirroring FY 2025 pattern.
- Customer forecasts and patent expiries guide capacity ramp-up; near full utilization expected as commercial launches increase.
- Anticipated launches of key products like Liraglutide, Teriparatide, and Semaglutide generics in FY 2026 across multiple markets.
- Market expansion driven by increased access in underserved regions (e.g., Brazil and Canada), with 4-12x potential volume growth.
- Investment of over $100 million underway for capacity and capability expansion to support future growth.
- New therapies, especially injectables, expected to sustain demand; oral therapy share capped at ~25%.
Profitability & Margins
See what OneSource Specialty Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities.
- Capacity is being increased from a rated 40 million to over 90 million by December 2025.
- Capacity additions are primarily in India, but the company is open to exploring expansion outside India, both organically and inorganically.
- Customer participation in capex is part of arrangements to secure capacity (e.g., take-or-pay contracts, reservation fees).
- The company is adding new capabilities, such as high-viscous pre-filled syringes, within its broader platform.
- Investments also include integration programs, upgrading IT systems, and improving digitalization and quality standards.
- The company targets debt reduction aligned with capex and has reduced net debt to INR4,707 million as of March 2025, aiming for net debt-free status in 2-3 years.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Specialty Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- OneSource Specialty Pharma has a strong and growing order book with around 50 ongoing drug-device combination (DDC) projects, including both fully delivered and in-execution.
- The order book is aligned with customers' forecasts and patent expiries over the next 2-3 years, supporting capacity ramp-up.
- The company is actively adding capacity, aiming to nearly double rated capacity from about 40 million to over 90 million by the end of 2025.
- Capacity expansions are primarily to serve ongoing Master Service Agreements (MSAs) and Customer-Specific Agreements (CSAs).
- Customers have provided take-or-pay contracts and long-term forecasts, ensuring secured capacity allocations.
- The robust order book underpins the company’s FY '28 guidance of $400 million in sales, supporting continued growth through FY '26 and into FY '27.
- The broad and diverse customer base reduces dependency on any single approval or market.
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Specialty Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules Ltd (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q4 FY25 results?
OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.